Open Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: A Phase 2 Biomarker Study	Involved	26	0
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women	Leading	0	0

Closed Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
PLCO Ovarian Phase III Validation Study	Involved	50	1
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study	Involved	55	2

Publications

Publication Name	PubMed ID	Journal
A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses.	36037307	Clin Cancer Res
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.	37402882	Oncogene
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.	38195887
Biomarkers and Strategies for Early Detection of Ovarian Cancer.	33051337	Cancer Epidemiol Biomarkers Prev
Cell Origins of High-Grade Serous Ovarian Cancer.	30424539	Cancers (Basel)
Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.	30967390	Cancer Prev Res (Phila)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.	30835824	Cancer
Early Detection of Ovarian Cancer.	30390764	Hematol Oncol Clin North Am
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.	28637689	Clin Cancer Res
Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.	31714597	Cancer
In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes.	29131572	ACS Appl Mater Interfaces
Next steps in the early detection of ovarian cancer.	34676377	Commun Med (Lond)
Normal Risk Ovarian Screening Study: 21-Year Update.	38194613
Novel Approaches to Ovarian Cancer Screening.	31346778	Curr Oncol Rep
Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.	31035430	Cancers (Basel)
Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis.	32092936	Cancers (Basel)
Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers.	41053579	Clin Proteomics
Screening for ovarian cancer: imaging challenges and opportunities for improvement.	28639753	Ultrasound Obstet Gynecol
Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.	30709840	Cancer Prev Res (Phila)
The National Cancer Institute Early Detection Research Network: Two Decades of Progress.	33262198	Cancer Epidemiol Biomarkers Prev
The role of biomarkers in the management of epithelial ovarian cancer.	28468520	Expert Rev Mol Diagn

Interests

Early detection of ovarian cancer

Our laboratory has been dedicated to developing an effective screening strategy for early stage of ovarian cancer. Having discovered CA125, we have collaborated with Drs. Karen Lu and Steven Skates to develop a two-stage strategy where rising CA125 analyzed by the risk of ovarian cancer algorithm (ROCA) triggers transvaginal sonography (TVS) in a small fraction of postmenopausal women at average risk for developing ovarian cancer, the NROSS study. If TVS identifies a pelvic mass, surgery is undertaken. More than 35,000 annual blood specimens have been obtained from >6,800 women over the last 19 years. Less than 2% of participants have undergone TVS each year, prompting 24 operations and detecting 15 cases of ovarian cancer - two borderline and 15 invasive - with 10 (67%) in stage I or II. No more than 3 operations were required to detect each case of ovarian cancer. Similar specificity has been observed in a United Kingdom trial (UKCTOCS). While the UKCTOCS demonstrated a 20% improvement in mortality, confidence limits around this estimate are large and additional observation is needed to validate this estimate. To detect cases missed by CA125, we have evaluated >110 biomarkers to identify a panel that includes CA125, HE4, and CA72-4 . Statistical techniques are being developed that will permit use of multiple markers to improve sensitivity without sacrificing specificity. Nearly 5,000 women continue to participate in the NROSS screening study. A new algorithm is being developed that will be evaluated in this population.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Site

The University of Texas MD Anderson Cancer Center

Degree(s)

M.D.

Email

rbast@mdanderson.org

Fax

713-792-7864

Person ID

1911

EDRN Title

EDRN Principal Investigator

Note

To update contact information, please visit the Data Management and Coordinating Center .